ACP policy paper recommends ways to stem the rising cost of prescription drugs

March 28, 2016, American College of Physicians

The American College of Physicians (ACP) today released a new policy paper calling for changes that could slow the rising cost of prescription drugs. The paper, Stemming the Escalating Cost of Prescription Drugs, was published in Annals of Internal Medicine.

"In the United States we pay comparatively much more for prescription drugs than other countries, an increasing concern for all Americans," said Wayne J. Riley, MD, MPH, MBA, MACP, president of ACP. "The impact of these rising costs can be very detrimental to patients, causing them to forgo filling important prescriptions or not taking drugs on the schedule that they are prescribed."

The many issues surrounding prescription drug pricing are a complex problem. Because the research, development, regulatory and payment systems for prescription medication are deeply intertwined addressing the issue will take the combined efforts of many different stakeholders. Unlike other markets, competition alone may not be effective in encouraging innovation or controlling costs, especially without the price transparency required for true price competition.

To address the complex factors at play, ACP's paper offers a series of recommendations aimed at addressing and slowing down the rate of price increase for . ACP:

  • Supports transparency in the pricing, cost, and comparative value of all pharmaceutical products.
  • Supports the elimination of restrictions on using quality adjusted life years in .
  • Supports novel approaches, including: allowing price negotiation by Medicare and other publicly-funded health programs, consideration of reimporting drugs manufactured in the United States, and policies and programs to increase competition for sole-source drugs.
  • Opposes extending market or data exclusivity periods beyond what is currently granted.
  • Supports approaches to encourage value-based decision making, including value frameworks, bundled payments, indication-specific pricing and evidence-based benefit designs that include explicit consideration of the pricing, cost, value, and comparative effectiveness of included in a health plan's benefit package.
  • Believes that payers that use tiered or restrictive prescription drug formularies must ensure that patient cost-sharing is not set at a level that imposes a substantial economic barrier to patients.
  • Believes that biosimilar drug policy should aim to limit patient confusion between originator and biosimilar products.

"We continue to pay more and more for drugs, making it harder and harder for patients to afford critical prescriptions. This situation must change," concluded Dr. Riley. "A prescription drug can only be as effective as a patient's ability to access it and adhere to the medication as prescribed. Year after year of rising costs is clearly a burden for many patients that ultimately impacts their health and quality of life."

Explore further: Spending on prescription meds up about 5 percent in 2015

More information: Annals of Internal Medicine, www.annals.org/article.aspx?doi=10.7326/M15-2768

Related Stories

Spending on prescription meds up about 5 percent in 2015

March 17, 2016
(HealthDay)—Spending on prescription medications for insured Americans increased about 5 percent in 2015, with the increase half of that seen in 2014, the Associated Press reported.

ACP: Doctors should prescribe generic medications whenever possible

November 23, 2015
All clinicians should prescribe generic medications whenever possible as a way to improve adherence to therapy and clinical outcomes while containing costs, the American College of Physicians (ACP) advises in a new paper ...

Medicare to test new payment model for some outpatient drugs

March 8, 2016
Medicare proposed a nationwide experiment Tuesday into new ways to pay for drugs administered in a doctor's office, including many cancer treatments.

Expect more drug coverage changes as cost-control push grows

February 23, 2016
CVS Health is refining its prescription for controlling drug costs, and patients can expect more frequent coverage changes as the pharmacy benefits manager scours data and reacts quicker to expense spikes.

Oral chemo still too expensive even after doughnut hole closes

December 8, 2015
Access to expensive oral chemotherapy drugs will still be out of reach for millions of Americans with Medicare coverage, even when one of the most touted reforms in health care coverage takes place in 2020. The analysis, ...

Studies show high out-of pocket costs limit access to lifesaving specialty drugs

March 28, 2016
"Specialty drugs" have become important treatment options for many serious and chronic diseases, and in some conditions like cancer they represent the only chance for long-term survival. But, insurers increasingly require ...

Recommended for you

Researchers publish study on new therapy to treat opioid use disorder

May 22, 2018
Better delivery of medications to treat opioid use disorder (OUD) is key to addressing the opioid crisis and helping the 2.6 million Americans affected by the disease.

Could nonprofit drug companies cut sky-high prices?

May 17, 2018
(HealthDay)—Generic prescription drugs should be cheap, but prices for some have soared in the United States in recent years. Now a group of U.S. hospitals thinks it has a solution: a nonprofit drug maker.

Fewer antibiotics for kids, but more ADHD drugs

May 15, 2018
(HealthDay)—American kids are taking fewer prescription medications these days—but certain drugs are being prescribed more than ever, a new government study finds.

Opioid makers' perks to docs tied to more prescriptions

May 14, 2018
Doctors who accept perks from companies that make opioid painkillers are more likely to prescribe the drugs for their patients, new research suggests.

Less is more when it comes to prescription opioids for hospital patients, study finds

May 14, 2018
In a pilot study published in JAMA Internal Medicine, Yale researchers significantly reduced doses of opioid painkillers given to hospital patients. By delivering the opioids with a shot under the skin or with a pill instead ...

Generic options provide limited savings for expensive drugs

May 7, 2018
Generic drug options did not reduce prices paid for the cancer therapy imatinib (Gleevec), according to a Health Affairs study released today in its May issue.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.